Fentanyl sublingual - INSYS Therapeutics

Drug Profile

Fentanyl sublingual - INSYS Therapeutics

Alternative Names: Fentanyl SL spray - INSYS Therapeutics; Fentanyl sublingual spray - INSYS Therapeutics; Subsys

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator INSYS Therapeutics, Inc
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain
  • Phase II Postoperative pain

Most Recent Events

  • 10 Feb 2017 INSYS Therapeutics completes a phase II trial for Post-operative pain in USA (Sublingual) (NCT02915978)
  • 01 Dec 2016 Phase-II clinical trials in Postoperative pain in USA (Sublingual) (NCT02915978)
  • 26 Sep 2016 INSYS Therapeutics plans a phase II trial for Post-operative pain in USA (Sublingual) (NCT02915978)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top